z-logo
Premium
Loratadine: Multiple‐Dose Pharmacokinetics
Author(s) -
Radwanski Elaine,
Hilbert James,
Symchowicz Samson,
Zampaglione Nicola
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb03061.x
Subject(s) - loratadine , pharmacokinetics , cmax , volunteer , chemistry , active metabolite , steady state (chemistry) , metabolite , radioimmunoassay , pharmacology , high performance liquid chromatography , antihistamine , chromatography , medicine , biology , biochemistry , agronomy
The steady‐state pharmacokinetics of loratadine (L), a new long‐acting antihistamine devoid of CNS activity, was investigated in 12 healthy male volunteers. Each volunteer received 40‐mg L capsules q24h for ten days. Blood samples were collected at various times on day 1, 5, 7, and 10 and assayed for L by radioimmunoassay (RIA) and for descarboethoxyloratadine (DCL), a known active metabolite, by high‐performance liquid chromatography (HPLC). The plasma L and DCL concentration‐time data in the disposition phases were fitted to a biexponential equation for pharmacokinetic analysis. Steady‐state plasma L Cmax concentrations were reached at 1.5 hour (Tmax) after each dose. DCL steady‐state Cmax values ranged 26 to 29 ng/mL at a Tmax ranging from 1.8 to 3 hours. The AUC at steady state, AUC τ , was 80 to 96 and 349 to 421 h × ng/mL for L and DCL, respectively. The accumulation indexes (Ra) based on AUC τ ratios, did not change for either compound after day 5. Ra values for L and DCL after the fifth dose were 1.4 and 1.9, respectively, indicating that there is little accumulation of either L or DCL after a multiple (once‐a‐day) dosage regimen. The t 1/2 β at steady state were 14.4 and 18.7 hours for L and DCL, respectively, which were similar to those reported following a single‐dose L administration. Observed plasma drug concentrations were in good agreement with predicted values derived for pharmacokinetic parameters.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here